Plasmodium falciparum is the most common malaria parasite in sub-Saharan Africa. It is responsible for the majority of severe malaria cases. It is observed that the Plasmodium falciparum malaria cases reported in our country are cases acquired from abroad. The first-line treatment for Plasmodium falciparum malaria is artemisinin-based combination therapy. A patient with a travel history to Sierra Leone, presenting with fever, chills, and nausea, vomiting, was diagnosed with Plasmodium falciparum-induced malaria. The patient was successfully treated with oral artemether-lumefantrine therapy. However, a relapse occurred 14 days later, likely due to treatment failure. Subsequent treatment with 7 days of intravenous artesunate followed by 3 days of artemether-lumefantrine tablet plus 10 days of doxycycline tablet resulted in treatment success. This case report aims to emphasize that in Plasmodium falciparum cases with vomiting or those who cannot tolerate oral medication, intravenous treatments should be given quickly and treatment should be completed with oral options when oral intake is good.
Plasmodium falciparum, Sahra altı Afrika'da en yaygın sıtma parazitidir. Şiddetli sıtma vakalarının çoğundan Plasmodium falciparum sorumlu tutulmaktadır. Ülkemizde bildirimi yapılan Plasmodium falciparum sıtma olgularının yurt dışı kaynaklı vakalar olduğu görülmektedir. Plasmodium falciparum sıtması için birinci basamak tedavi, artemisinin bazlı kombinasyon tedavisidir. Sierra Leone ülkesine seyahat öyküsü olan, ateş, üşüme-titreme, bulantı, kusma şikayeti olan hastaya Plasmodium falciparum’un etken olduğu sıtma tanısı konulmuş olup, artemeter-lumefantrin oral tedavi ile iyileşme sağlandı. Ancak 14 gün sonra olasılıkla tedavi başarısızlığı nedeniyle rekürrens gelişti ve 7 gün intravenöz artesunat sonrasında 3 gün artemeter-lumefantrin tablet + 10 gün doksisiklin tablet tedavisiyle tedavi başarısı sağlandı. Bu vaka sunumu ile kusması olan veya oral ilacı tolere edemeyecek Plasmodium falciparum olgularında hızlı bir şekilde intravenöz tedavilerin verilmesi ve oral alımı iyi olduğu zaman oral seçeneklerle tedavinin tamamlanması gerektiği vurgulanmak istendi.
Hastadan bilgilendirilmiş olur formu alınmıştır.
Bulunmamaktadır.
Hastanın tanı ve tedavi sürecinde emeği geçen sayın hocalarımıza, asistan doktor, intern doktor ve hemşirelerimize teşekkür ederiz.
| Primary Language | Turkish |
|---|---|
| Subjects | Health Management |
| Journal Section | Case Report |
| Authors | |
| Submission Date | September 25, 2023 |
| Acceptance Date | August 8, 2024 |
| Early Pub Date | December 6, 2024 |
| Publication Date | December 20, 2024 |
| IZ | https://izlik.org/JA89SU28FK |
| Published in Issue | Year 2024 Volume: 17 Issue: 3 |
MEU Journal of Health Sciences Assoc was began to the publishing process in 2008 under the supervision of Assoc. Prof. Gönül Aslan, Editor-in-Chief, and affiliated to Mersin University Institute of Health Sciences. In March 2015, Prof. Dr. Caferi Tayyar Şaşmaz undertook the Editor-in Chief position and since then he has been in charge.
Publishing in three issues per year (April - August - December), it is a multisectoral refereed scientific journal. In addition to research articles, scientific articles such as reviews, case reports and letters to the editor are published in the journal. Our journal, which has been published via e-mail since its inception, has been published both online and in print. Following the Participation Agreement signed with TÜBİTAK-ULAKBİM Dergi Park in April 2015, it has started to accept and evaluate online publications.
Mersin University Journal of Health Sciences have been indexed by Turkey Citation Index since November 16, 2011.
Mersin University Journal of Health Sciences have been indexed by ULAKBIM Medical Database from the first issue of 2016.
Mersin University Journal of Health Sciences have been indexed by DOAJ since October 02, 2019.
Article Publishing Charge Policy: Our journal has adopted an open access policy and there is no fee for article application, evaluation, and publication in our journal. All the articles published in our journal can be accessed from the Archive free of charge.

This work is licensed with Attribution-NonCommercial 4.0 International.